7th March 2024
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to: communications@curiumpharma.com
21st February 2024
Curium announces submission of the marketing authorization application for PYLCLARI®, an innovative (18F)-PSMA PET tracer indicated in adults with prostate cancer to Swissmedic
6th February 2024
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
21st November 2023
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
16th November 2023
Curium announces first patients in Europe injected with Pylclari® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
25th October 2023
Curium and PIUR IMAGING announce thyroid imaging partnership in Germany to enable tomographic 3D ultrasound solutions
7th September 2023
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
15th August 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th July 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th July 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st July 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
26th May 2023
Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent
23rd May 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd May 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th March 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd March 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
21st December 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th November 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd November 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th November 2022